Gene therapy products present a unique set of challenges for the control of host cell protein impurities.
Thorsten Strahl
Advertisement
Thorsten Strahl is supervisor protein and scientific officer with Charles River.
Articles by Thorsten Strahl
Advertisement
Latest Updated Articles
Detecting Residual HCPs Demands a Holistic ApproachJuly 15th 2021
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
4
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
5